











































Progress in identifying epigenetic mechanisms of xenobiotic-
induced non-genotoxic carcinogenesis
Citation for published version:
Terranova, R, Vitobello, A, Del Rio Espinola, A, Wolf, R, Schwarz, M, Thomson, J, Meehan, R & Moggs, J
2017, 'Progress in identifying epigenetic mechanisms of xenobiotic-induced non-genotoxic carcinogenesis',
Current Opinion in Toxicology, pp. 62-70. https://doi.org/10.1016/j.cotox.2017.06.005
Digital Object Identifier (DOI):
10.1016/j.cotox.2017.06.005
Link:




Current Opinion in Toxicology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
 1 
Progress in Identifying Epigenetic Mechanisms of Xenobiotic-Induced Non-Genotoxic 1 
Carcinogenesis  2 
 3 
Rémi Terranovaa,e, Antonio Vitobelloa,e, Alberto Del Rio Espinolaa, C. Roland Wolfb,e,  4 
Michael Schwarzc,e, John Thomsond,e, Richard Meehand.e, and Jonathan Moggsa,e* 5 
 6 
aPreclinical Safety, Translational Medicine, Novartis Institutes for BioMedical Research, Basel, CH-4057, 7 
Switzerland 8 
bDivision of Cancer Research, University of Dundee, United Kingdom 9 
cDepartment of Toxicology, University of Tübingen, Germany  10 
dMRC Human Genetics Unit, Institute of Genetics & Molecular Medicine, University of Edinburgh, United 11 
Kingdom 12 
eMember of IMI MARCAR consortium 13 
 14 




Determining the human relevance of structurally and functionally distinct non-genotoxic 19 
carcinogenic compounds that induce a diverse range of tissue-, gender-, strain- and species-20 
specific tumors in animals remains a major challenge for toxicologists. Nevertheless, 21 
elucidating mechanisms of xenobiotic-induced tumors in animals can provide industry, 22 
environmental and regulatory scientists with valuable tools for cancer hazard identification 23 
and risk assessment. The discovery that aberrant epigenetic events frequently accompany 24 
genetic mutations in human cancers has stimulated efforts to deploy integrated epigenomic 25 
and transcriptomic profiling of xenobiotic-induced non-genotoxic carcinogenesis (NGC) in 26 
animal models, enabling enhanced mechanistic interpretation and novel early biomarker 27 
discovery. Recent advances in the mapping and functional characterization of mammalian 28 
tissue-specific epigenomes also provides new opportunities to characterize the cross-29 
strain/-species chromatin architecture of non-genotoxic carcinogen effector genes and to 30 
predict their potential for modulation by xenobiotics in human tissue. Since xenobiotic-31 
induced perturbations of gene regulation are intimately associated with the underlying DNA 32 
sequence, there is a need to integrate the impact of genotype on susceptibility to NGC. 33 
Furthermore, the potential association of xenobiotic target modulation with tumorigenic 34 
phenotypes can be assessed using genetic models and cancer genome resources. Finally, we 35 
discuss how epigenomic profiling may be used to critically assess the comparability and 36 
validity of cellular NGC models versus in vivo-derived tissue samples and some of key 37 
challenges associated with incorporating epigenetic mechanisms and biomarkers into 38 
cancer risk assessment.  39 
 40 
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1. Introduction 44 
Concerns regarding the appropriateness of extrapolating lifetime rodent carcinogenicity 45 
study findings to humans have been extensively reviewed [1-3]. If xenobiotic exposure in 46 
animals is found to be associated with either tumor induction or early indicators of 47 
neoplastic hazard, then a weight of evidence-based cancer risk assessment is generally 48 
recommended. A key contributing factor to the weight of evidence approach for xenobiotic-49 
induced non-genotoxic carcinogenesis (NGC) is the determination of a mechanism or mode 50 
of action since this provides an entry point for subsequent assessments of potential human 51 
relevance [4,5] [Meek 2014]. A molecular basis for species-specific non-genotoxic 52 
carcinogenesis has been proposed for a number of compounds [4,5,10] [Meek 2014][Corton 53 
2014][Cohen 2010][Cohen and Arnold 2016]. However, the diverse range of xenobiotic-54 
induced tumor types that are typically observed in animal carcinogenicity studies, often 55 
exhibiting tissue-, gender-, strain- and/or species-specificities, make the determination of 56 
mechanism and assessment of potential relevance to humans very challenging. 57 
Furthermore, there is very little data on potential association of xenobiotic exposure with 58 
non-genotoxic carcinogenesis in humans due to the likely latency, very low incidence, and 59 
difficulty of deconvoluting environmental versus intrinsic factors for malignancy 60 
development. Some insight may be gained from somatic mutational signatures of human 61 
tumors that are associated with known mutagenic exposures [6] but there will inevitably be 62 
overlap between intrinsic and extrinsic mechanisms [7]. Despite these challenges, there is a 63 
need for rigorous cancer risk assessment of xenobiotics to which humans are exposed 64 
including treatment with novel therapeutics [8] and occupational or environmental 65 
exposure to chemicals [3]. 66 
 67 
Characterizing the molecular mechanisms underlying xenobiotic-induced non-genotoxic 68 
carcinogenesis has great potential for providing industry, environmental and regulatory 69 
scientists with valuable tools for cancer hazard identification and risk assessment. This is 70 
exemplified by phenobarbital-induced hepatocarcinogenesis where Constitutive Androstane 71 
Receptor (CAR)-mediated stimulation of mouse hepatocyte proliferation represents a mode 72 
of action that has not been reproduced in human hepatocytes in vitro [Hasmall and Roberts, 73 
1999; Hirose et al., 2009; Parzefall et al., 1991]. Since there is no clear evidence for 74 
phenobarbital-associated liver cancer risk in humans (based on epidemiological data from a 75 
large number of clinical studies including long-term therapeutic treatment of epileptics; [9]), 76 
CAR-mediated liver non-genotoxic carcinogenesis is not generally considered to be human-77 
relevant [4,10]. Humanized rodent models in which mouse livers have been engineered to 78 
express human CAR supported proliferative responses and tumor promotion following 79 
exposure to PB [11-13]. In contrast, human hepatocytes did not support hyperplastic 80 
responses to the phenobarbital in chimeric mice with humanized liver [14]. It is noteworthy 81 
that the observed plasma phenobarbital exposures in these humanized models was 82 
comparable to those obtained in human subjects receiving therapeutic doses of this drug. 83 
Thus, understanding the opposing outcomes of these models will require further 84 
characterization of: i) quantitative exposure-response relationships; ii) the influence of 85 
human nuclear receptor-mouse gene regulatory protein interactions; iii) the influence of 86 
mouse host cellular environment on grafted human hepatocytes; and iv) comparability at 87 
the molecular, biochemical and cellular levels of engineered or grafted hepatocytes to 88 
human donor-derived liver tissue. Importantly, phenobarbital induces extensive changes in 89 
chromatin modification patterns across the regulatory regions of CAR target genes in mouse 90 
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liver [15-17] and it is thus plausible that differences in the genetic and epigenetic 91 
architecture of phenobarbital effector genes play a role in determining species-specific 92 
susceptibility to CAR-mediated hepatocarcinogenesis.  93 
 94 
Here we describe how recent advances in epigenetic regulation of the genome can be 95 
leveraged to provide new insights into molecular mechanisms of xenobiotic-induced non-96 
genotoxic carcinogenesis, to identify early biomarkers and susceptibility factors, and to 97 
enable new approaches for assessing potential human relevance. 98 
 99 
 100 
2. Leveraging recent advances in cancer epigenetics to enhance mechanistic interpretation 101 
and biomarkers of non-genotoxic carcinogenesis 102 
Epigenetics describes mechanisms that operate in concert with the underlying DNA 103 
sequence to regulate gene expression and determine the overall phenotype of cell. 104 
Epigenetic marks include the methylation of DNA cytosine bases, post-translational 105 
modifications of histone proteins, nucleosome remodeling, and non-coding RNAs. These 106 
epigenetic marks are dynamically regulated by numerous enzymes and binding proteins that 107 
enable cells to read, write or erase chromatin modifications. Epigenetic formatting of the 108 
genome contributes to spatio-temporal patterns of gene expression and controls lineage 109 
choice, differentiation and cellular functions [18]. Epigenetic variation, together with 110 
genetic variation and meta-genomic variation, thus represents one of the key drivers of 111 
phenotypic variation in health and disease.  The acquisition of cancer hallmarks such as 112 
sustained proliferative signaling and resistance to cell death [19] is facilitated by a 113 
combination of genome instability, mutation and epigenomic disruption [20]. Epigenetic 114 
perturbations associated with cancer etiology and progression include widespread 115 
mutations in epigenetic regulatory proteins and aberrant expression of stem cell 116 
reprogramming genes [21]. Epigenetic mechanisms of carcinogenesis that are well 117 
characterized in humans include estrogen exposure and breast cancer [22]. Importantly, 118 
from a toxicologic perspective, inflammatory responses to tissue injury and chronic 119 
exposure to environmental factors have been proposed as mechanisms for inducing cancer-120 
predisposing epigenetic changes in vulnerable populations of somatic stem cells and 121 
progenitor compartments [23]. It is noteworthy that environmental influences on 122 
intermediary metabolism such as nutrient availability and utilisation can also result in tumor 123 
growth-promoting modifications of the epigenetic landscape by altering substrates and 124 
inhibitors of chromatin-modifying enzymes [23-27]. Epigenetic signatures of environmental 125 
exposure (e.g. to cigarette smoke) have already been identified in humans and are likely to 126 
exist for many other types of xenobiotic exposure in both humans and animals [28]. 127 
 128 
Together, these observations are stimulating efforts to investigate whether xenobiotic-129 
induced perturbations of DNA methylation, chromatin modification, non-coding RNAs, 130 
and/or transcription factor accessibility contribute to non-genotoxic carcinogenesis 131 
[16,17,29-35].  132 
 133 
 134 
3. Elucidating early epigenetic molecular indicators of non-genotoxic carcinogenesis  135 
Integrated epigenomic and transcriptomic profiling of target tissues for xenobiotic-induced 136 
tumors represents a powerful approach for elucidating early molecular indicators of non-137 
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genotoxic carcinogenesis. This is exemplified by a series of mechanistic in vivo rodent 138 
studies conducted within the EU IMI MARCAR consortium (www.imi-marcar.eu) in which 139 
tumor promoting doses of phenobarbital were used as a reference rodent liver tissue-140 
specific non-genotoxic carcinogen. In addition to the anticipated activation of CAR/-catenin 141 
signalling pathways and induction of proliferation markers, novel early biomarkers include 142 
the aberrant up-regulation of pluripotency-associated non-coding RNAs, dynamic changes in 143 
locus-specific chromatin modifications and altered transcription factor activity.  144 
 145 
Phenobarbital progressively upregulated long non-coding RNAs encoded by an 146 
epigenetically imprinted Dlk1-Dio3 gene cluster in mouse perivenous hepatocytes in a CAR 147 
and -catenin dependent manner [32]. Importantly, perturbation of this gene locus has 148 
been associated with mouse stem cell pluripotency [36,37] and also with a stem-cell like 149 
phenotype in a subset of human hepatocellular carcinomas [38]. Furthermore, hepatocytes 150 
in the same perivenous region of mouse liver were recently associated with Wnt-signalling 151 
dependent stem cell-like properties [39]. Together these observations raise the intriguing 152 
possibility that PB-induces dedifferentiation/reprogramming of adult hepatocytes to a stem 153 
cell-like state during mouse hepatocarcinogenesis. The notion that functional and molecular 154 
hallmarks of pluripotent stem cells [40] might represent a valuable source of early NGC 155 
biomarkers warrants further research.  156 
 157 
It is widely accepted that deregulation of normal DNA methylation and gene expression 158 
patterns can aid cancer cells to evolve more rapidly and thus contribute to increased 159 
invasiveness, metastatic potential and potentially drug resistance [41]. Phenobarbital 160 
induced both acute and long-lasting changes in the mouse liver DNA methylome with 161 
dynamic and reciprocal changes in 5-methylcytosine (5mC) and 5-hydroxymethylcytosine 162 
(5hmC) levels within regulatory regions of CAR and -catenin gene targets [17]. 163 
Furthermore, early phenobarbital-induced loss of 5hmC in a specific subset of gene loci 164 
predicts subsequent aberrant promoter 5mC hypermethylation in resultant phenobarbital-165 
promoted mouse liver tumors [34]. Recent evidence suggests that genomic loci exhibiting 166 
elevated levels of 5hmC represent dynamic chromatin states in contrast to loci marked by 167 
5mC which are typically regarded to indicate inactive chromatin states. Consistent with this 168 
notion, the majority of enriched 5hmC is found to be associated with gene bodies, a large 169 
number of enhancer elements, and a small subset in gene promoters, in a transcription-170 
dependent manner. Thus, the profiling of xenobiotic-induced changes in tissue-specific 171 
5hmC levels has significant potential for classifying the mode of action of potentially 172 
carcinogenic agents [41]. 173 
 174 
Significant progress has been made in identifying target genes for a diverse range of NGC 175 
modes of action via transcriptomic profiling of rodent tissues [42,43]. Proximal regulatory 176 
transcription factors and upstream signalling pathways can often be inferred for well 177 
characterized target genes and have been extensively validated for the NGC-associated 178 
nuclear receptors CAR and Peroxisome Proliferator Activated Receptor alpha (PPAR using 179 
biochemical, cellular and rodent genetic models. A complementary and powerful approach 180 
for identifying gene regulatory interactions underlying NGC involves computational 181 
modelling of predicted transcription factor binding sites within NGC-responsive genes and 182 
has been used to identify novel roles for E2F and ZFP161 transcription factors in regulating 183 
PB-mediated hepatocyte proliferation and subsequent tumor promotion [33]. 184 
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 185 
4. Towards functional and cross-species epigenomic characterization of xenobiotic-186 
induced non-genotoxic carcinogenesis 187 
Importantly, multiple layers of epigenetic marks and gene regulatory factors control 188 
genome structure and function. Recent advances in the development of deep sequencing 189 
based chromatin modifications and accessibility assays enable genome-wide functional 190 
characterization of mammalian tissue-specific epigenomes. This is exemplified by the recent 191 
completion of genome-wide epigenome profiles for >100 human tissues and cell types 192 
[44,45] (http://epigenomesportal.ca/ihec/index.html) that is dramatically enhancing our 193 
understanding of genome function and regulation.  194 
 195 
Genome-wide chromatin profiling methods including DNase I hypersensitivity and Assay for 196 
Transposase Accessible Chromatin (ATAC) assays have been integrated with histone post-197 
translational modification mapping to identify the open cis-regulatory DNA regions (also 198 
known as the cistrome) that are recognised by trans-acting regulatory factors. Cistrome 199 
elements include gene enhancers, promoters, insulators, silencers and locus control regions. 200 
Cistrome profiling has identified hundreds of thousands of enhancer regions in the human 201 
and mouse genomes, encompassing 1-3% of the genome, and vastly outnumbering the 202 
number protein coding genes, overall highlighting the importance of the regulatory fraction 203 
of the genome [44,46,47]. Enhancers are bound by regulatory transcription factors and 204 
integrate extracellular signaling pathways with intracellular cell fate information to elicit cell 205 
type-specific transcriptional responses [48] The functional binding of regulatory 206 
transcription factors to these cis-acting accessible sites orchestrates long-range regulatory 207 
interactions in the 3D space of the nucleus, enabling cell-type specific, spatiotemporal, 208 
control of gene expression patterns which drive cell identity and function [49-51]. 209 
Furthermore, enhancers represent regulatory modules associated with the most conserved 210 
phase of vertebrate embryogenesis and are subject to conserved developmental regulation 211 
by epigenetic modifiers [52]. Importantly, the role of enhancer dysfunction in cancer has 212 
been extensively characterized [53,54]. Single enhancers and dense clusters of enhancers 213 
(known as “Super”-enhancers in the literature) appear to control the expression of core 214 
transcription factors (TFs) underlying cell identity [54-56] and are often deregulated in 215 
cancer leading to aberrant activation of growth related genes and deregulation of important 216 
lineage specific differentiation drivers [54,57].  217 
 218 
Together these observations suggest that integrated cistrome, chromatin modification and 219 
transcriptome profiling of NGC target tissues will provide novel mechanistic insights and 220 
may provide unique opportunity to characterize the cross-strain and cross-species 221 
chromatin architecture and transcription factor accessibility of non-genotoxic carcinogen 222 
effector genes. 223 
 224 
Although access to blood or tissue samples from humans exposed to putative NGCs is very 225 
rare, a variety of human tissue-specific epigenomes representing both healthy and disease 226 
states (http://ihec-epigenomes.org/) can in principle be leveraged as comparators to NGC 227 
target tissue epigenomes in animal models. We envisage that the potential human 228 
relevance of well-defined NGC mechanisms in animals could be explored by evaluating the 229 
degree of conservation and dynamic range of chromatin modifications/accessibility at 230 
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regulatory regions of orthologous non-genotoxic carcinogen effector genes in human tissue 231 
samples (Figure 1). It is noteworthy that comparison of mode of action-related target gene 232 
architecture in human versus animal tissue may circumvent some of the challenges 233 
associated with the comparability of cultured human cells or humanized rodent models to 234 
human tissue. Importantly, any proposed species-differences in NGC molecular signaling 235 
pathways needs to be integrated with quantitative differences in the potency and 236 
level/exposure of xenobiotics and intrinsic tissue mutation rates. 237 
 238 
5. Influence of genotype on epigenetic mechanisms of xenobiotic-induced non-genotoxic 239 
carcinogenesis 240 
Since xenobiotic-induced perturbations of gene regulation are intimately associated with 241 
the underlying DNA sequence, there is a need to integrate the impact of genotype on  242 
susceptibility to non-genotoxic carcinogenesis.  243 
Distinct strains and species of preclinical animal models have been shown to widely vary in 244 
their susceptibility to xenobiotic-induced carcinogenicity. For example, mouse stocks and 245 
inbred strains can significantly differ in their susceptibility to treatment-induced liver 246 
neoplasia, with C3H males being highly sensitive compared to highly resistant C57BL/6 247 
males, although this is likely to be based on both genetic and non-genetic factors [58]. Such 248 
strain differences in xenobiotic-induced liver tumors primarily affect tumor progression (or 249 
tumor size) and to a much lower part tumor number. Whilst specific liver tumor 250 
susceptibility genes have not yet been identified, several hepatocarcinogenesis 251 
susceptibility (Hcs) loci have been identified using mouse backcrosses and linkage analysis 252 
[59, 60]. Intriguingly, hsc3 maps within 6 megabases of the PB-responsive Dlk1-253 
Dio3 imprinted gene cluster on chromosome 12 [32][61]. Thus, transcriptional responses 254 
from this epigenetically imprinted gene cluster may be influenced by strain-specific genetic 255 
factors that could be further characterized via deep sequencing of appropriate inbred 256 
mouse strains.  257 
 258 
The recent integration of human genome regulatory DNA and disease- and trait-associated 259 
genetic variants reveals a disproportionate (>80%) enrichment of disease-associated genetic 260 
variants in non-coding enhancer regions, potentially disrupting important transcription 261 
factor-based regulatory interactions in a cell-type specific manner [49,55,62,63]. These cis-262 
acting non-coding regulatory variants range from rare to common and are associated with a 263 
broad range of phenotypic effects driven by sometimes subtle effects on target gene 264 
expression [64]. The role of non-coding sequence variants in cancer is currently being 265 
explored [65] but it seems likely that genetic variants in non-coding enhancer regions will 266 
contribute to tissue-, strain- and species-specific responses to NGC.  267 
 268 
It is also noteworthy that most rodent carcinogenicity studies are currently performed in 269 
genetically undefined outbred stocks (e.g. CD1 mouse and/or Wistar rat) that represent a 270 
very narrow range of genetic diversity compared to humans. Whilst using more diverse 271 
panels of rodent strains might conceivably enable improved predictions of inter-individual 272 
human variability [66], the feasibility of testing xenobiotics for carcinogenicity in multiple 273 
rodent strains is limited by ethical and economic factors. Nevertheless, the genetic diversity 274 
in mice provides a powerful approach for establishing mechanism. 275 
 276 
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In the context of pharmaceutical and agrochemical product development, the ability to 277 
deploy early mechanism-based approaches for cancer hazard identification prior to entering 278 
more resource intensive and costly late phase preclinical and/or clinical studies would be 279 
highly advantageous. Molecular characterization of the potential association of drug target 280 
modulation with tumorigenic phenotypes via genetic models, germline mutation databases 281 
and cancer genome resources has recently been proposed as an innovative strategy for 282 
enhanced cancer hazard identification [8]. Where the molecular target of non-therapeutic 283 
xenobiotic NGCs can be defined through mechanistic studies, similar genetic approaches 284 
could be leveraged to help derisk the potential association of xenobiotic target modulation 285 
with tumorigenic phenotypes. For example, is there a cancer phenotype associated with 286 
genetic variants or genetic modifications of xenobiotic target genes? Are tumor suppressor-287 
like somatic mutation spectrums associated with genes encoding xenobiotic targets in 288 
human cancers? Emerging cancer epigenome mapping resources should also be integrated 289 
to strengthen these xenobiotic target gene assessments. 290 
 291 
 292 
6. Conclusion and Perspectives 293 
Whilst substantial progress has been made in identifying epigenetic mechanisms and 294 
biomarkers of xenobiotic-induced non-genotoxic carcinogenesis in animal models, 295 
determining the human relevance of structurally and functionally distinct non-genotoxic 296 
carcinogenic compounds that induce a diverse range of tissue-, gender-, strain- and species-297 
specific tumors in animals still remains a major challenge for toxicologists, although several 298 
rodent NGC modes of action are generally accepted as not being relevant for humans 299 
[4,5,10] [Meek 2014][Corton 2014][Cohen 2010][Cohen and Arnold 2016]. A number of 300 
human cellular models and humanised rodent genetic models have been deployed for NGC 301 
hazard identification but these are unlikely to fully recapitulate human 302 
tissue responses to xenobiotic exposure. Given the likely importance of epigenetic 303 
mechanisms during NGC it is particularly noteworthy that the DNA methylation profiles of 304 
mammalian cells differ from those of the primary tissues from which they were derived 305 
due to rapid reprogramming of epigenetic and transcriptional profiles following adaptation 306 
of primary cells to culture [67]. The recent refinement of cistrome, 307 
epigenome and transcriptome profiling tools for assessing cross-species conservation of 308 
tissue-specific genome functions provides a valuable opportunity to critically assess the 309 
comparability and validity of cellular NGC models versus in vivo-derived tissue samples. 310 
Furthermore, 5-hydroxymethylcytosine profiling is proving to be a powerful tool for cell 311 
lineage tracing [41] and thus may help deconvolute the cell type specificity of xenobiotic  312 
responses within complex tissues. 313 
 314 
Finally, there are several challenges associated with incorporating epigenetic mechanisms 315 
and biomarkers into cancer risk assessment. These include the need to define the normal 316 
inter-individual dynamics of healthy versus disease-state epigenomes across tissues and 317 
species, and also to determine what constitutes adverse versus adaptive epigenetic changes   318 
in response to xenobiotic exposure 68,69]. However, 319 
efforts are already underway to characterize tissue-specific epigenomes from rodent stocks 320 
and strains that are regularly used for carcinogenicity testing (http://cefic 321 
lri.org/projects/c3-ed-a-comprehensive-epigenomic-profile-of-liver-tissue from-rat and 322 
mouse) and phenotypic anchoring of mechanism-based epigenetic NGC biomarkers 323 
 8 
provides a way forward towards defining adversity at the molecular pathway level.   324 
 325 
Figure 1.  Xenobiotic signaling to chromatin and potential for species differences in 326 
regulation of NGC effector genes. 327 
A) Potential for species differences in NGC signaling mechanisms have been extensively 328 
explored at the level of ligand-receptor interactions. For example, phenobarbital activation 329 
of the CAR nuclear receptor in hepatocytes and subsequent transcriptional up-regulation of 330 
xenobiotic response genes is highly conserved between rodents and humans. In contrast, 331 
human hepatocytes appear to be refractory to the proliferative effects of phenobarbital 332 
that are seen in rodents [Hasmall and Roberts, 1999; Hirose et al., 2009; Parzefall et al., 333 
1991] and this is not fully accounted for by species differences in CAR-ligand interactions 334 
alone. We hypothesise that, although the molecular mechanisms responsible for the acute 335 
xenobiotic responses appear to be highly conserved across species (Target Gene a/A), 336 
secondary effectors implicated in the transduction of the extracellular signals to the nucleus 337 
and the chromatin landscape configuration of NGC effector genes are likely to contribute to 338 
strain and species differences in susceptibility to non-genotoxic carcinogens (Target Gene 339 
b/B). Such mechanistic differences in NGC molecular signaling pathways need to be 340 
integrated with potential quantitative differences in the potency/level of exposure of 341 
xenobiotics and intrinsic tissue mutation rates. B) Illustration of conserved (blue) and 342 
species-specific (red) differences in chromatin accessibility of liver tissue gene loci based on 343 
visualization of ENCODE DNase I mouse and human datasets via the UCSC browser 344 
(https://genome.ucsc.edu/; [44,70]; GEO dataset accession numbers GSE90306 and 345 
GSM1014195, John Stamatoyannopoulos, UW). Underlying DNA sequence similarity is 346 
shown as dotplots based on local genomic alignment between orthologous mouse (y axis) 347 
and human (x axis) regions (images obtained using YASS tool; [71]). Housekeeping gene 348 
(GAPDH), liver tissue-specific gene (ALB), xenobiotic response gene (CYP2B6; orthologous to 349 
mouse Cyp2b10), candidate non-coding RNA biomarker for CAR-mediated liver tumor 350 
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